A Closer Look: BMS Strikes First China-only Deal By In-licensing Mature CV Drug From Kyowa Hakko Kirin
This article was originally published in PharmAsia News
Executive Summary
To enrich its cardiovascular pipeline in China, BMS strikes its first “China only” deal to in-license a hypertension drug already on China’s NDRL from Kyowa Hakko Kirin.
You may also be interested in...
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.